USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS
First Claim
1. A method for reducing or lessening the severity of clinical symptoms associated with PCV2 infection, lessening the overall porcine circovirus load of an animal, and/or reducing the immunosuppressive effect of porcine circovirus infection in pigs comprising administering a porcine circovirus type 2 antigen to a pig.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
15 Citations
28 Claims
- 1. A method for reducing or lessening the severity of clinical symptoms associated with PCV2 infection, lessening the overall porcine circovirus load of an animal, and/or reducing the immunosuppressive effect of porcine circovirus infection in pigs comprising administering a porcine circovirus type 2 antigen to a pig.
-
13. A method for improving the level of general disease resistance of pigs comprising administering a porcine circovirus type 2 antigen to a pig.
- 14. A process for the production of a medicament for reducing or lessening the severity of clinical symptoms associated with PCV2 infection, lessening the overall porcine circovirus load of an animal, or reducing the immunosuppressive effect of porcine circovirus infection, said process comprising the steps of obtaining a porcine circovirus antigen, and combining said antigen with veterinary-acceptable carriers, pharmaceutical-acceptable carriers, or immunomodulatory agents.
- 16. The use of a porcine circovirus type 2 antigen for the preparation of a medicament for reducing or lessening the severity of clinical symptoms associated with PCV2 infection, lessening the overall porcine circovirus load of an animal, and/or reducing the immunosuppressive effect of porcine circovirus infection in pigs, wherein said medicament is administered to a pig.
-
28. The use of a porcine circovirus type 2 antigen for the preparation of a medicament for improving the level of general disease resistance of pigs.
Specification